[{"orgOrder":0,"company":"AlloVir","sponsor":"Kalaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"TH103","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AlloVir \/ Kalaris Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"AlloVir \/ Kalaris Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for TH103

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The combined company will focus on the development of TH103, a fully humanized, recombinant fusion protein, for patients with neovascular age-related macular degeneration.

                          Brand Name : TH103

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 08, 2024

                          Lead Product(s) : TH103

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Kalaris Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank